Skip to content

Fusion Antibodies PLC Sustainability Reports

Fusion Antibodies PLC operates as a contract research organization (CRO) that provides pre-clinical antibody discovery, engineering, and expression services. The company specializes in antibody humanization, cell line development, and antigen expression to help speed up drug development for pharmaceutical, biotech, and diagnostic clients.

Sector: Professional & technical services

Country: United Kingdom

Exchange: London Stock Exchange (AIM)

ISIN: GB00BDQZGK16

8 reports from 2018 to 2025